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Surgery is the gold therapeutic standard for patients affected with stage I non-small cell lung
cancer. Stereotactic ablative radiotherapy is currently considered the preferred treatment
option for inoperable patients, representing approximately 25%. Limited data are available
directly comparing surgery and SABR in operable patients, none of them prospective. Pre-
liminary results are encouraging, showing that the two treatment modalities are equally
effective in terms of tumour control, with expected similar survival projections. Moreover,eywords:
arly stage lung cancer
tereotactic radiotherapy
horacic surgery
in  elderly patients SABR could represent a valid treatment alternative in comparison to
surgery due to the lower morbidity. We  here review and discuss the potential role of SABR
as  an alternative to surgery in operable early stage lung cancer patients.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All.  Background
urgery currently represents the standard treatment option
or patients affected with early stage non-small cell lung
ancer (NSCLC). Long-term results of surgical resection show
urvival rates of 60–70% at 5 years, as high as 80% in selected
eries.1 Lobectomy or pneumonectomy improves outcomes if
ompared with sub-lobar resection, but a substantial propor-
ion of patients are ineligible for surgery due to the presence of
oncomitant medical conditions such as respiratory or cardio-
ascular comorbidities, associated with a high risk of surgical
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complications. Moreover, a small group of patients refuse
surgery. An observation alone strategy has been shown in the
past to obtain worse outcomes if compared to surgery or radi-
ation, and it is now considered inappropriate in the majority
of cases.2 Until recently, patients unﬁt for surgery typically
underwent conventionally fractionated radiotherapy with a
total dose of 60–70 Gy delivered over a 6- to 7-week period.
The poor outcome achievable with conventional radiotherapyy – Radiation Oncology Unit, Via Genova 3, 10126 Torino, Italy.
gmail.com (A.R. Filippi).
is reﬂected in the Surveillance, Epidemiology and End Results
(SEER) study, showing a global cancer speciﬁc 5-year survival
rate of 15%.3 Stereotactic body radiotherapy (SBRT) or stereo-
tactic ablative radiotherapy (SABR) represents an emerging
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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treatment option and a new standard of care for stage I NSCLC
in inoperable patients. Due to the long-term efﬁcacy and the
low rate of late toxicity,4 SABR might be considered a valid
alternative to surgery also in operable patients.
2.  Aim
The present review provides a focus on the scientiﬁc basis and
clinical data supporting the potential role of SABR as an alter-
native to surgery in operable patients, as a step towards a more
tailored therapy for early stage NSCLC.
3.  SABR  vs.  conventional  radiotherapy  in
inoperable  patients
Results of conventional external beam radiation for early
stage NSCLC are disappointing,5 with local relapse as the
predominant pattern of failure leading to different 5-year
survival rates according to primary tumour dimensions: 38%
for patients with tumours < 2 cm,  22% for tumours between
2 and 3 cm,  5% for tumours between 3 and 4 cm and 0% for
larger lesions.6 In order to improve tumour control and, hence,
cancer-speciﬁc survival (CSS), dose-escalation gained credit as
an option, but when considering the dose–response relation-
ship for lung cancer, doses up to 80–90 Gy would be needed to
control approximately 50% of the tumours.7,8 Dose-escalation
achieved by conventionally fractionated radiotherapy is
limited by 2 main factors: a prolonged overall treatment time,
resulting in a considerable amount of tumour repopulation,
and an increased radiation dose delivered to the functional
lung tissue, with a possible further functional impairment.
SABR, a radiation technique characterised by the use of
very accurate repositioning and advanced image-guidance
techniques, allows the administration of few large fractions
able to kill the neoplastic cells through radio-ablation at very
high biologically equivalent doses (BED > 100 Gy). To date, the
largest report on the efﬁcacy of SABR in stage I NSCLC is the
one from Vrije University in Amsterdam9: 676 patients were
treated and 124 (18%) had disease recurrence, with a median
follow-up time of 32.9 months. Actuarial 5-year rates of local,
regional, and distant recurrence were 10.5%, 12.7% and 19.9%,
respectively. Of the 124 recurrences, 82 (66%) were distant
and 57 (46%) were isolated distant recurrences. Isolated loco-
regional recurrences occurred in the remaining 42 patients
(34%). The median times to local, regional, and distant recur-
rence were 14.9, 13.1 and 9.6 months, respectively, and CSS at 5
years exceeds 60%. In this series all patients were staged with
CT–PET and had either histological conﬁrmation or “proof of
malignancy.” Delivered doses were 54–60 Gy in 3 fractions to
peripheral tumours, 55–60 Gy in 5 fractions for lesions close to
chest wall and 60 Gy in 8 fractions for central tumours. This
large series conﬁrms, with an adequate follow up time, the
promising results of many  mono-institutional Phase II clin-
ical trials.10–13 In 2010, Radiation Therapy Oncology Group
(RTOG) 0236 Trial mature results were published, showing an
OS rate at 3 years of 55.8%, with a 97.6% LC rate (median
follow-up 34.4 months).14 These favourable clinical outcomes
resulted in a signiﬁcant practice modiﬁcation in the last yearsiotherapy 1 9 ( 2 0 1 4 ) 275–279
for inoperable patients, mainly represented by elderly patients
with comorbidities. Palma et al. showed, in a population-based
time-trend analysis, that the proportion of patients aged >75
years with stage I NSCLC treated with radiotherapy with rad-
ical intent increased from 26% in the interval 1999–2001 to
32% in 2002–2004 and 42% in 2005–2007. These changes trans-
lated into a signiﬁcant increase in OS rate for stage I lung
cancer elderly patients globally treated in 2005–2007 (surgery
and/or radiotherapy, p < 0.001), and particularly in the subset
of patients treated with radiotherapy (p < 0.056 at log-rank test
comparing 1999–2001 with 2005–2007).15 As the results achiev-
able with SABR are signiﬁcantly superior to those achievable
with conventional radiotherapy, SABR is currently considered
the preferred treatment option for inoperable patients with
stage I NSCLC, and efforts towards the conﬁrmation of these
ﬁndings by a prospective randomised comparison with con-
ventional radiotherapy have been abandoned.
3.1.  Open  issues  in  SABR  for  inoperable  patients
3.1.1.  Histological  diagnosis
Histological conﬁrmation of lung nodules in SABR series has
been a concern since the introduction of this treatment. The
majority of patients referred to Radiation Oncology Depart-
ments are elderly and/or with comorbidities: hence, in most
of them, there is contraindication to CT-guided Fine Needle
Aspiration; in adjunct, peripheral nodules may be difﬁcult
to reach by bronchoscopy. As a result, in most series a cor-
rect histological diagnosis is available in 50–60% of patients.
There are several reports comparing the outcomes between
patients with or without histological diagnosis: in the series
by Takeda et al.,16 56 patients without histological diagnosis
and 115 patients with conﬁrmed NSCLC were compared, and
local control and survival probability at 3 years after SABR
were almost identical for patients with or without histolog-
ical conﬁrmation. In the Vrije University series,9 histological
conﬁrmation before SABR was obtained in 235 (35%) of 676
patients; the remaining patients had a new or growing lesion
with a CT appearance consistent with malignancy and local
18FDG-PET uptake, since the likelihood of a benign diagnosis
in such patients is less than 4%.17,18
3.2.  Central  and  large  tumours
An increased risk for severe-fatal toxicity was recorded when
treating central tumours at high doses per fraction in pio-
neering studies. Centrally located lesions are in proximity to
critical structures such as trachea, bronchial tree or oesoph-
agus, all tissues characterised by a serial architecture, with
high risk of toxicity for large doses per fraction. In the Indi-
ana University series, a 11-fold increase risk of severe toxicity
was evident for central tumours treated with 60–66 Gy in 3
fractions. Grade 3 or higher toxicity during 2 years of follow-
up was noted for 46% of patients with central tumours, with
6 eventual treatment-related deaths occurred.19 Afterwards,
with risk-adapted treatment schedules (60 Gy in 7.5 Gy  frac-
tions), excellent rates of controls were reported also in central
tumours.20 Milano et al.21 reviewed outcomes and toxicity of
SABR in 2009, including published experiences with differ-
ent total dose/fractionation protocols, and showed that with
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dapted fractionation schedules the risk of severe toxicity
ecome comparable to peripheral lesions with similar out-
omes in terms of tumour control.
In large tumours, namely those with a diameter > 6 cm,
ABR has been poorly investigated and few clinical data are
vailable. As reported by Ong et al., on 18 patients treated
ith SABR for tumours exceeding 80 cm3,22 the risk of symp-
omatic pneumonitis is higher, and dosimetric parameters
uch as MLD,  contralateral V5, ipsilateral V5 and total lung
5 become essential and should be included as critical dose-
olume constraints in planning evaluation. Further clinical
ata are needed before considering SABR a safe treatment in
his patients’ population.
.3.  Late  toxicity  and  quality  of  life
BRT toxicity rate appears very low in all series. Acute toxi-
ities include radiation pneumonitis in a minority of patients
nearly 5%) and skin reactions exclusively when high doses
re delivered with a limited number of ﬁelds and skin doses
xceed 50% of prescription dose. Typical radiological changes
fter SABR are well documented, and acute ﬁndings include
iffuse consolidation (in approximately 20–30%), patchy con-
olidation (10–20%), diffuse ground glass opacities (less than
0%) and patchy ground glass opacities (10–15%). Late radio-
ogical changes are very common (approximately 70%), as
anifestations of radiation ﬁbrosis, and consist of modiﬁed
onventional pattern, mass-like pattern or scar-like pattern.
hese radiological ﬁndings apparently do not translate in clin-
cally signiﬁcant impaired pulmonary function. Ohashi et al.
bserved no signiﬁcant changes in Total Lung Capacity, Vital
apacity or FEV1 before or 1 year after SABR for small periph-
ral lung tumours.23 Similar results were reported by Stephans
t al. in a retrospective study on 92 patients.24 When the tar-
eted lesions are in close proximity to the chest wall, speciﬁc
hronic toxicities might include thoracic pain and/or rib frac-
ures; brachial plexopathy is a dose-limiting toxicity in SBRT
reatment of apical tumours.
Quality of life has been poorly investigated in patients
ubmitted to SABR. Widder et al. compared 2 prospective
ohorts of inoperable patients with T1-2N0M0 primary lung
umours, receiving either 70 Gy in 35 fractions with 3D-CRT
r 60 Gy in 3–8 fractions with SABR25: Global quality of life
GQoL), physical functioning (PF), and patient-rated dyspnoea
ere assessed using the respective dimensions of EORTC
LQ-C30 and LC13. GQoL and PF were stable after SABR,
hile dyspnoea increased after SABR by only 3.2 out of 100
oints. Patients self-assessed GQoL has also been studied by
agerwaard et al.,26 with questionnaires given at 3, 6, 12,
8 and 24 months after treatment. QOL data were collected
rospectively using the EORTC QLQ-C30 in 382 consecutive
atients, with 86% judged unﬁt for surgery, and 14% declin-
ng surgery. Data were available for 382 patients at baseline
nd for 282, 212, 144, 56, and 43 patients at 3, 6, 12, 18, and 24
onths post-SABR, respectively. Except for a non-signiﬁcant
ecrease in 2–3 points per year in physical functioning, no
tatistically or clinically signiﬁcant worsening of any of the
oL functioning or symptom scores at any follow-up time
oint was observed. Very recently, results of a prospectivetherapy 1 9 ( 2 0 1 4 ) 275–279 277
evaluation of QoL after SABR in 26 patients conﬁrmed these
ﬁndings.27
4.  SABR  vs.  surgery  in  operable  patients
Few clinical reports are available on operable patients refusing
surgery and treated with SABR, as surgery is the recognised
standard of care. In some retrospective series, few patients
refusing surgery were included in separate subgroups. In a
Japanese multi-institutional study on 87 operable patients,
SABR achieved a LC rate of 92% for T1 and 73% for T2 tumours,
with 55 months median follow-up. Five-year OS rates were
72% for stage IA and 62% for stage IB.28 Similar results were
obtained by the group Vrije University group.29 The local
control rate achievable with SABR appears comparable to
lobectomy, and the high reported OS rates are mainly due
to the lower number of non-cancer related deaths. In a 2010
retrospective study by Grills et al.,30 124 patients ineligible
for anatomic lobectomy were compared: 55 underwent SABR
while 69 underwent wedge resection. Study endpoints were
local recurrence (LR), regional recurrence (RR), loco-regional
recurrence (LRR), distant metastases (DM), freedom from any
failure (FFF), overall survival (OS) and cancer-speciﬁc sur-
vival (CSS). Respiratory functional tests were similar for both
groups. At 30 months, no signiﬁcant differences were identi-
ﬁed in RR, LRR, DM or FFF between the two groups (p = 0.16).
SABR reduced the risk of LR compared to wedge resection
4% vs. 20% (p = 0.07), but OS was higher with wedge. Palma
et al.31 compared surgery and SABR in elderly patients by
a matched-pair analysis using population-based data, and
found no difference in mortality between the 2 treatments.31
A total of 120 patients could be matched (60 surgery, 60 SBRT),
with a median age of 79 years. Median follow-up was 43
months, and 30-day mortality was 8.3% after surgery and
1.7% after SBRT. OS at 1 and 3 years was 75% and 60% after
surgery, and 87% and 42% after SBRT, respectively (log-rank
p = 0.22). In 2012, Senan et al. presented at the American Soci-
ety of Clinical Oncology Annual Meeting the results of a study
comparing SABR with Video-Assisted Thoracoscopic Surgery
(VATS) Lobectomy.32 The matched cohort consisted of 128
patients with cT1-3N0 NSCLC following SABR (n = 64) or VATS-
lobectomy (n = 64). Median follow-up times were 30 and 16
months, respectively. SABR patients had better LRC rates at
1 and 3 years (96.8% and 93.3% vs. 86.9% and 82.6%, respec-
tively, p = 0.03). Three-year PFS, distant recurrence rates and
OS did not signiﬁcantly differ.
Currently there are 2 registered trials recruiting patients
and comparing SABR vs. surgery in early stage NSCLC. The ﬁrst
one is from Mayo Clinic, and it is a Phase II randomised trial of
sub-lobar resection vs. SABR in high-risk patients (clinicaltri-
als.gov identiﬁer NCT01622621), with the number of patients
alive at 2 years as primary study endpoint and 96 patients to be
enrolled. The second one is the Accuray Cyberknife® study, a
prospective randomised Phase III trial comparing radiosurgery
to surgical resection in stage I NSCLC (STARS study proto-
col, clinicaltrials.gov identiﬁer NCT00840749), with OS at 3
years as primary endpoint. The Phase III multi-centre ran-
domised trial ROSEL, initiated in 2008 to establish the role
of stereotactic radiotherapy in patients with operable stage
d rad
r
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IA lung cancer (clinicaltrials.gov identiﬁer NCT00687986) was
early terminated due to poor recruitment.
5.  Discussion  and  future  perspectives
Twenty-ﬁve percent of patients with stage I NSCLC are not
eligible for lobectomy due to medical contraindications: in
these patients SABR can be now considered the standard
choice, even in centrally located tumours and in patients with
poor pulmonary function. In the remaining 75% of patients,
surgery is the cornerstone of therapy and the best hope for
cure. Reﬁnements in surgical techniques and perioperative
care reduced treatment-related mortality in the last years,
now approximately 1%. Anatomical resection is globally supe-
rior to limited surgery, but in small peripheral lesions (<3 cm)
sub-lobar resection (rather than wedge resection) can be con-
sidered adequate. For central and larger lesions, this approach
is not feasible. The few cited retrospective studies investigat-
ing a direct comparison between these 2 treatment modalities
showed surprising results, as the comparison was in favour
of SABR for all endpoints (loco-regional control and survival).
As the study by Senan et al. was presented only in abstract
form, ﬁnal results are needed to properly comment its ﬁnd-
ings. The study by Grills et al. has some ﬂaws that have been
extensively discussed by Atorki et al. in the same issue of the
Journal of Clinical Oncology in 2010.33 The two populations
differ because the SABR series is prospective, while the sur-
gical one is an historical series. This difference is important
as the characteristics of the 2 populations in terms of comor-
bidities or respiratory function might be non-comparable.
Moreover, the surgical arm has a longer follow-up, with a
consequent higher probability of late events. Another major
criticism could be that wedge resection is not considered
the standard surgical procedure, as it is associated with a
higher risk of recurrence if compared with lobectomy or with
segmentectomy.34 It has to be noted that in the study by Grills
et al.,30 patients were deﬁned as “marginally operable,” a sub-
group they refer to as “borderline surgical candidates,” with
underlying cardiovascular/respiratory problems for which a
loss of function – including sublobar anatomic resection or
non-anatomic wedge resection would be an issue. In this
subgroup, SABR probably offers control rates comparable to
surgery, but these results cannot be considered consistent
enough to consider SABR an option outside clinical trials.
At the same time, as underlined by Robert Timmerman,35 a
prospective Phase III study between anatomic surgery and
radiotherapy, two disparate treatment modalities, is difﬁcult
to realise in practice, as patients do not easily accept the
randomisation, with difﬁculties in enrolment and early ter-
mination. As there is still need of a prospective comparison of
two well balanced populations, probably less invasive surgery
(for example video-assisted segmentectomy) might be com-
pared vs. SABR in stage I patients, like in the Phase II study by
Mayo Clinic. In clinical practice, probably a multidisciplinary
approach could be of great value in determining the best treat-
ment strategy in every single patient, taking into account
factors like respiratory function, tumours dimension and loca-
tion, age and comorbidities and offering the proper choice in
terms of efﬁcacy and morbidity. In the cited study by Palmaiotherapy 1 9 ( 2 0 1 4 ) 275–279
et al. dealing with elderly patients31 (median age 79 years
old) SABR, a non-invasive, out-patient treatment had a 30-day
mortality rate of <2% in a high-risk population, and this ﬁnd-
ing can be of particular importance for decision making, as
patients are adverse to taking risks that involve the possibil-
ity of short-term death. A Markov-model based comparison of
surgery vs. SABR for patients aged 65 or older predicted that
surgery might confer an overall survival beneﬁt of 2–3% at 5
years over SBRT. However, once operative mortality increases
above 4%, the survival advantage of surgery was negated and
SBRT preferred.36
In conclusion, probably surgery has a potential rival in early
stage NSCLC, and in the future SABR might be more  used
in one patients’ subgroup, while surgery will continue to be
used in another. At the same time, quality assurance proce-
dures and standardisation of stereotactic treatments in terms
of dose prescription and delivery techniques are warranted
in order to offer the best available therapy in every Radiation
Oncology Department.
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